ClinicalTrials.gg
WithdrawnNCT04977310Updated Dec 16, 2024

TARGET-LOAD Pilot Study Comparing Hemodynamics-guided LVAD Unloading Vs. Standard of Care

An interventional study of CardioMEMS in Heart Failure, sponsored by STAVROS G DRAKOS. Withdrawn at 2 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-12-16.

Sponsored by STAVROS G DRAKOS · Not applicable, Interventional, and Treatment

How we know

Why this study was withdrawn
Did not receive funding from sponsor

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,159 studies in Heart Failure with a site in United States — 346 open to participants now, 439 under way, 27 of them phase 3. Heart Failure · United States.

Enrollment
1,523rd of 1,602
0 · median 66
Started
2025
with 107 others
No phase
887 of 2,159
159 open now
Registered
1,606th of 2,159
by date

Among the 2,159 studies in Heart Failure with a site in United States, this one is the 1,523rd largest by enrollment of the 1,602 interventional ones that give a count, is one of 108 that started in 2025, is one of 887 with no phase, and was the 1,606th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

346 of the 2,159 studies in Heart Failure with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,159 studies in Heart Failure with a site in United States, or all of them as a file.
02

Study summary

This study is a prospective, randomized-controlled, non-blinded, multi-center, pilot trial to compare standard-of-care left ventricular assist device (LVAD) unloading plus heart failure (HF) medications reverse-remodeling management versus hemodynamics-guided LVAD unloading with use of the wireless monitoring system CardioMEMS plus HF medications reverse-remodeling management.

Read the detailed description

LVADs are being increasingly used in end-stage heart failure patients as a bridge to transplant (BTT) or as a destination therapy (DT). Although LVAD recipients are considered to be optimally unloaded with speed optimizations following LVAD implantation, re-hospitalizations due to HF recurrence are far from negligible. Recent studies have reported that at least 35% of hospital readmissions post-LVAD implantation are due to HF exacerbations, volume status changes or other cardiac causes (arrhythmias etc.). This suggests that patients are being sub-optimally unloaded and/or taking inadequate medical therapy and probably this decreases the chances for potential reverse remodeling and myocardial recovery. Moreover, a recent study demonstrated that cardiac dimensions obtained from echocardiography do not adequately reflect the degree of mechanical unloading of the heart. It has also shown strong evidence that pulmonary artery (PA) pressures monitoring can be reliably used to assess the pulmonary capillary wedge pressure (PCWP) and left ventricular end-diastolic pressure (LVEDP).

Symptomatic heart failure exacerbation requiring hospital admission may lie at the end of a spectrum of worsening hemodynamics that are unable to be detected before the manifestation of symptoms and limits the potential for myocardial recovery. Therefore, it is proposed that repeatedly adjusting LVAD pump flow speed and tailoring standard HF medications depending on the patient's PA pressure acquired from the CardioMEMS device can optimize pressure and volume unloading and promote reverse cardiac remodeling and recovery.

Clinical experience with LVAD support has shown that a subset of LVAD patients can experience reverse cardiac remodeling and significant improvement of myocardial function suggesting that LVAD-induced mechanical unloading of the failing heart may be a plausible therapeutic strategy aiming at myocardial recovery and device removal. These explanted patients have shown "myocardial plasticity" in clinical studies and that they can be responsive and sensitive to load changes. These patients will be carefully monitored to prevent increased load and wall stress to drive again the detrimental spiral of cardiac remodeling and HF recurrence, which appears to be the case in at least one third of LVAD patients after device weaning. Along the same lines, the results from another clinical study showed a significant and large reduction in hospitalization for HF patients who were managed with CardioMEMS. Therefore, further improvement of patients' HF management will depend mainly on better identification and pro-active management of their fluid and hemodynamic status. It is proposed that chronically adjusting HF medications using CardioMEMS-guided hemodynamic assessment in patients who have weaned from LVAD support could improve long-term durability of cardiac improvement after LVAD weaning.

03

Conditions studied

  • Heart Failure

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Severe clinical HF resistant to intensive medical therapy and requiring LVAD implantation
  • \<=25% and cardiomegaly at time of LVAD implantation
  • Non-ischemic etiology of HF
  • Undergone LVAD implantation within prior 4 weeks or planned for LVAD implant
  • History of HF \< 5 years
  • \<=35 kg/m\^2
  • Pulmonary artery branch diameter between 7 - 15 mm
  • Female subjects of childbearing age with negative urine or serum pregnancy test and agreeing to use reliable mechanical or hormonal form of during study

Exclusion criteria

Exclusion Criteria:

  • Evidence of active acute myocarditis confirmed by histology
  • History of previous cerebrovascular accident resulting in significant fixed motor deficit, limiting ability to perform exercise testing
  • Implanted mechanical aortic and/or mitral valve(s) and/or right heart valve(s)
  • Aortic valve closure
  • Hypertrophic obstructive cardiomyopathy or sarcoidosis
  • Left ventricular end-diastolic diameter below normal (restrictive cardiomyopathy)
  • Irreversible multi-organ failure
  • Diagnosis of psychiatric disease, irreversible cognitive dysfunction or poor psycho-social issues likely to impair compliance with study protocol
  • Any condition that could limit survival to less than 2 years
  • History of cardiac or other organ transplant
  • to anti-coagulation, antiplatelet therapy, or diagnosis of coagulation disorders
  • Require acute or chronic renal replacement therapy within 3 months prior to enrollment
  • Participation in any other clinical investigations involving another Mechanical Circulating Support device or HF-related drug
  • Active infection
  • History of recurrent (>1) pulmonary embolism or deep vein thrombosis
  • Unable to tolerate right heart catheterization
  • Implantation of cardiac re-synchronization therapy \< 3 months before enrollment
  • Congenital heart disease
  • or allergy to aspirin and/or clopidogrel
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • No intervention
    Control

    After LVAD implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using echocardiographic imaging and other standard-of-care practices. During the Unloading phase, patients are serially evaluated with echocardiograms to assess for cardiac recovery, and LVAD explantation performed when predefined criteria are met. After explantation, patients undergo cardiac rehab and regular follow up.

  • Experimental
    Intervention

    After LVAD and wireless monitoring system (CardioMEMS) implantation, patients undergo cardiac rehab and pump speed will be optimized to maximize left ventricular unloading using CardioMEMS. During the Unloading phase, invasive hemodynamic guidance (via CardioMEMS) will be utilized to optimize pressure and volume unloading along with serial echocardiographic evaluations to assess for cardiac recovery, and LVAD explantation will be considered. After explantation, patients will undergo cardiac rehab and regular follow up with adjustments of HF medications based on the CardioMEMS-guided hemodynamic assessment.

    Device: CardioMEMS

Interventions

  • DeviceCardioMEMS

    Cardio-MEMS-guided Post-LVAD cardiac unloading and recovery

06

What researchers measure

Primary outcomes

  1. Proportion of subjects that meet explantation criteria by month 12 post-LVAD implantation, have LVAD explanted and retain left ventricular ejection fraction >=45% at 12 months post-LVAD weaning

    Removal of LVAD happens when subject meets all five of the following explantation criteria: (1) left ventricular end-diastolic diameter \< 60mm; (2) left ventricular end-systolic diameter \< 50mm; (3) left ventricular ejection fraction \> 45%; (4) left ventricular end-diastolic pressure \<= 15 mmHg; (5) resting cardiac index \> 2.4 L/min/m\^2

    Time frame: 24 months

Secondary outcomes

  1. Hospital Admissions

    Proportion of subjects admitted to the hospital for HF exacerbations at any time point during the study

    Time frame: 24 months

  2. Six-minute Walk Test

    Subject performance during six-minute walk test at 12 months after LVAD implantation

    Time frame: 12 months

07

Study locations

2 sites
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Inova Heart and Vascular Institute
    Falls Church, Virginia 22042, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Sep 2026, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 15, 2021
First posted
Jul 26, 2021
StartEst.
Mar 31, 2025
Primary completionEst.
Sep 1, 2026
CompletionEst.
Sep 1, 2026
Last update
Dec 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04977310
Lead sponsor
STAVROS G DRAKOS
Collaborators
Abbott
Responsible party
STAVROS G DRAKOS (Professor, Cardiovascular Medicine, University of Utah) — Sponsor-investigator
First posted
Jul 26, 2021
Start date
Mar 31, 2025 (estimated)
Primary completion
Sep 1, 2026 (estimated)
Completion
Sep 1, 2026 (estimated)
Last update
Dec 16, 2024

Study contacts

Stavros Drakos, M.D.
principal investigator · University of Utah

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion